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Abstract
The mechanisms underlying PSEN1 mutation-associated spastic paraparesis (SP) are not clear. We 
compared diffusion and volumetric magnetic resonance measures between 3 persons with SP 
associated with the A431E mutation and 7 symptomatic persons with PSEN1 mutations without 
SP matched for symptom duration. We performed amyloid imaging and central motor and 
somatosensory conduction studies in one subject with SP. We found decreases in fractional 
anisotropy and increases in mean diffusivity in widespread white matter areas including the corpus 
callosum, occipital, parietal, and frontal lobes in PSEN1 mutation carriers with SP. Volumetric 
measures were not different and amyloid imaging showed low signal in sensorimotor cortex and 
other areas in a single subject with SP. Electrophysiological studies demonstrated both slowed 
motor and sensory conduction in the lower extremities in this same subject. Our results suggest 
that SP in carriers of the A431E PSEN1 mutation is a manifestation of widespread white matter 
abnormalities not confined to the corticospinal tract that is at most indirectly related to the 
mutation’s effect on APP processing and amyloid deposition.
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1. Introduction
Alzheimer’s disease (AD) is the most common cause of neurodegenerative dementia and an 
estimated 5.3 million Americans are currently afflicted by it(Alzheimer's, 2015). Of these 
persons, an estimated 200,000 are below aged 65(Alzheimer's, 2015) and a subset of these 
have autosomal dominant AD (ADAD). ADAD is an early onset form of AD caused by the 
presence of essentially fully-penetrant mutations in one of three genes; Presenilin 1 
(PSEN1), Presenilin 2 (PSEN2) or Amyloid Precursor Protein (APP). The observation that 
pathogenic mutations in these genes affect cleavage of APP(Scheuner et al, 1996) is 
supportive evidence for a pivotal role of the β-amyloid (Aβ) protein in the etiology of 
AD(Hardy and Selkoe, 2002). Though increased relative or absolute production of the 42-
amino acid length version of Aβ (Aβ42) has been reproducibly demonstrated in 
ADAD(Ringman et al, 2008), such overproduction is less evident in late-onset AD (LOAD). 
The prevailing hypothesis for the development of LOAD is a diminished ability to eliminate 
Aβ, leading to its aggregation and deposition(Tanzi et al, 2004). Despite this apparent 
difference, both LOAD and ADAD share pathological features including neurofibrillary 
tangles(Ringman et al, 2016) and most often present with memory and executive deficits as 
well as personality changes(Ringman et al, 2011; Ringman et al, 2015). However, a 
significant subset of persons with ADAD, particularly when due to PSEN1 mutations, can 
have features atypical for AD including early myoclonus, pseudobulbar affect, and gait 
abnormalities due to spastic paraparesis (SP)(Joshi et al, 2012). SP can be the initial 
symptom, occur concurrently with, or somewhat after cognitive and behavioral changes in 
PSEN1-related ADAD and occurs in association with specific mutations(Karlstrom et al, 
2008; Larner, 2013). The pathologic basis of SP and other clinical variants in PSEN1-related 
AD is controversial(Rudzinski et al, 2008; Yokota et al, 2003) and it is unclear whether it is 
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related to qualitative or quantitative differences in APP processing, differences in the 
localization of resulting pathology(Martikainen et al, 2010), or other effects of PSEN1 
mutations(Xia et al, 2015).
The development of diffusion-weighted (DWI) magnetic resonance imaging (MRI) has 
allowed for sensitive delineation of white matter pathology in vivo (Bozzali et al, 2002; 
Medina et al, 2006). DWI measures both the direction and magnitude of proton diffusion. 
Such diffusion can be characterized by overall magnitude (mean diffusivity or MD) and 
tendency for the diffusion to be directionally dependent. Diffusion direction can be 
characterized by fractional anisotropy (FA): an index of the tendency of water to diffuse in a 
single direction obtained by calculating a diffusion tensor for each voxel (i.e. diffusion 
tensor imaging or DTI). Proton diffusion in white matter is typically parallel to fiber tracts 
and therefore FA and other DTI indices provide measures of white matter integrity(Ringman 
et al, 2007) and may distinguish demyelinating from degenerative processes(Song et al, 
2003). DTI can help delineate anatomical white matter changes but SP in PSEN1-related 
AD, has not been well described electrophysiologically. Such characterization can help 
delineate the nature and extent of white matter tract involvement.
Through the development of ligands that bind relatively selectively to fibrillar amyloid and 
can be radioactively labeled to allow detection using positron emission tomography 
(“amyloid PET”), we can now identify and localize amyloid deposition during life(Klunk et 
al, 2003). The relationship between the distribution of such pathology to defined anatomical 
pathways can help elucidate the role amyloid plaques play in symptom manifestation. In the 
current paper we sought to comprehensively assess the MRI characteristics of white matter 
involvement in SP in 3 carriers of the A431E PSEN1 mutation relative to 7 persons 
symptomatic from PSEN1 mutations but without SP. Furthermore, we performed additional 
assessments with amyloid PET using Pittsburgh Compound B (PiB) and motor and 
somatosensory evoked potential studies in one A431E PSEN1 mutation carrier with SP.
2. Methods
2.1 Subjects
Subjects or their surrogates gave written informed consent as part of an IRB-approved 
observational study of ADAD at UCLA. The ten subjects that were included were 
symptomatic from known pathogenic PSEN1 mutations, were aware of their mutation status, 
and had DTI available. Subjects underwent comprehensive clinical evaluations including the 
Mini-Mental Status Examination(Folstein et al, 1975) and Clinical Dementia Rating 
scale(Morris, 1997). The CDR is a global scale of dementia severity based on an interview 
with the subject and a knowledgeable informant. A score of 0 represents normalcy, 0.5 
indicates questionable or mild impairment, 1 mild, 2 moderate, and 3 severe dementia. The 
subjects were defined as having SP if leg spasticity interfered with their ability to ambulate 
before or within two years of the onset of cognitive symptoms. Time since onset of cognitive 
or motor symptoms was quantified in years. Subjects also underwent APOE genotyping 
using standard techniques.
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2.2 Image Acquisition
All subjects underwent structural T1-weighted MRI scans and DTI. All subjects but one 
(without SP) underwent Susceptibility Weighted Imaging (SWI) or T2-star weighted (T2*) 
MR from which microhemorrhage (MCH) count could be evaluated. Eight subjects 
underwent fluid attenuated inversion recovery (FLAIR) MRI sequences (3 with SP and 5 
without) and 5 subjects had a PiB PET scan (one with SP and 4 without).
All MR images were obtained on the same 3T Siemens Trio Scanner using a 32-channel 
phased array head-coil. The DTI protocol has been previously described(Ryan et al, 2013) 
and consisted of 64 gradient directions acquired via a single-shot spin-echo echo planar 
imaging (EPI) sequence (FOV 240 mm, matrix 96x96, yielding an isotropic voxel of 
2.5x2.5x2.5mm3 and 55 contiguous axial slices, TR=6800ms, TE=91ms, b-value=1000s/
mm2, augmented with parallel imaging acceleration (GRAPPA)). Nine acquisitions without 
diffusion weighting (b=0s/mm2) were also acquired.
All subjects also underwent volumetric structural T1 weighted imaging using MPRAGE, 
obtained in the sagittal plane (TR=2300ms, TE=2.95ms, voxel resolution=1.1x1.1x1.2mm3). 
To evaluate for the presence of MCHs, 6 subjects underwent SWI in the axial plane 
(TR=28ms, TE=20ms, voxel resolution=0.7x0.7x2.4mm3) and 3 underwent T2* in the axial 
plane (TR=650ms, TE=20ms, voxel resolution=0.8x0.8x4mm3). To evaluate for the presence 
and extent of white matter hyperintensities (WMH), 8 subjects underwent axial T2 weighted 
FLAIR MRI imaging (TR=9000ms, TE=90ms, voxel resolution=0.9x0.9x5.0mm3).
Five subjects also underwent a PiB scan (one with SP, “AJ”, and 4 without). PiB imaging 
was performed with a bolus injection of approximately 15 mCi of [11C]PiB. Dynamic 
acquisition consisted of either a 70-minute scan starting at injection or a 30-minute scan 
beginning 40 minutes post-injection.
2.3 Image processing and analysis of DTI data
DTI processing was performed using the Diffusion Weighted Imaging Toolbox in FSL 
(http://www.fmrib.ox.ac.uk/fsl/). Prior to processing, the two diffusion sequences were 
averaged and then concatenated with the 9 B0 acquisitions to create a single 4D volume for 
processing. For one subject without SP, only one DTI volume was acquired. Volumes were 
subjected to eddy current correction and linear realignment to the first image. Diffusion 
tensors were then calculated after applying a brain mask generated from FSL’s Brain 
Extraction Tool. The resulting Fractional Anisotropy (FA), Mean Diffusivity (MD), axial 
diffusivity (AD) and radial diffusivity (RD) maps were used for analysis. Conversion of all 
outputs to standard space was achieved via FSL’s Tract Based Spatial Statistics (TBSS) 
toolbox, which performed nonlinear registration to FSL’s FA template map followed by a 
sequential nonlinear and affine transformation into MNI space. The processed FA images 
were then combined to generate a mean FA image for the group, which was used to create a 
mean FA “skeleton” to limit voxel statistics to white matter. A threshold of 0.20 was used to 
include white matter (WM) tracts that were both common to all subjects and the most 
aligned, while excluding potential non-WM regions. Individual subject FA images were then 
projected onto this skeleton to create skeletonized FA images for statistical analysis.
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2.4 Volumetric analyses
The MPRAGE images of all subjects were registered in the same space and automatically 
segmented to obtain cortical reconstruction and volumetric segmentation using FreeSurfer 
v5.1 (http://surfer.nmr.mgh.harvard.edu/). Visual inspection of the automated segmentation 
was done for quality control. Eleven regions of interest (ROIs) were selected. The cortical 
thicknesses of the frontal, parietal, temporal, and occipital lobes, and the volume of the 
cerebellum, hippocampus (left and right), caudate, putamen, pallidum, and amygdala of each 
subject were normalized by their intracranial volume and used for structural and atrophy 
analyses.
2.5 Microhemorrhage count
The number of MCH on SWI and T2* images were manually counted by author N J-M and 
reviewed and confirmed by author TB.
2.6 White Matter Hyperintensities
The degree of periventricular white matter hyperintensity (WMH) was scored on FLAIR 
images by author N J-M and confirmed by author TB using Fazekas’ scale(Fazekas et al, 
1987). Quantification of WMH volume was performed using a Matlab/SPM tool developed 
in house at Washington University. Briefly, the volume of voxels with an intensity above a 
specified threshold in segmented white matter volumes from FLAIR images were totaled.
2.7 PiB PET analyses
C11-PIB PET images were analyzed using NeuroQ (Syntermed Inc, Atlanta, 
www.syntermed.com). After correction for tissue-based attenuation NeuroQ implements an 
algorithm for automatically measuring the number of radioactive events emitted by a 
positron source per second from pixel locations assigned by a computerized reconstruction 
algorithm as falling within 240 standardized planar regions of interest (ROI) defined on each 
transaxial plane of the PET scan. These regions were defined after each PET scan was 
transformed to the NeuroQ template space. The 240 NeuroQ transaxial regions are then 
automatically grouped into 47 3D standardized volumes of interest (sVOI) corresponding to 
distinct neuroanatomical (e.g. left inferior parietal lobule) or functional areas (e.g., Broca’s 
area) as previously described(Torosyan and Silverman, 2012). All mean activity values are 
automatically normalized to the mean pixel activity measured in the cerebellar cortex 
producing standard uptake volume ratio (SUVR) units.
2.8 Electrophysiological Measures
Electrophysiological measures were also performed on subject AJ. Central motor conduction 
time (CMCT) was computed by establishing the total M-wave latency by stimulating the left 
motor cortex while recording the latency of a motor evoked potential (MEP) in the right first 
dorsal interosseous muscles (FDI) and tibialis anterior muscle. F-wave latency to these 
muscles was then calculated and half this latency was subtracted from the M-wave latency to 
determine the CMCT. Somatosensory evoked potentials (SSEPs) from the right arm and leg 
were assessed by stimulating the median nerve at the wrist and the posterior tibial nerve at 
the ankle. Upper limb SSEPs were recorded from the ipsilateral Erb’s point (N9), over the 
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fifth cervical spinal process and contralateral parietal scalp (N20). Lower limb SSEPs were 
recorded from the ipsilateral popliteal fossa (N8) and scalp (P37). CMCT and SSEP 
latencies on the index patient were compared against gender and height matched laboratory 
standards.
2.9 Statistical analysis
All of the imaging analyses described above were performed blind to the presence of SP. 
Comparisons of demographic variables and quantitative and semi-quantitative imaging 
variables were then made between subjects with and without SP using two-tailed chi square 
tests (and Fisher’s exact tests when appropriate) and Mann-Whitney U tests for categorical 
and ordinal/numerical variables using SPSS (version 23).
For DTI, voxel-wise statistical analyses were performed via a permutation-based inference 
randomized program in FSL to compare differences between subjects with and without SP. 
The threshold of the resulting statistical maps was set to p < 0.05 corrected at the cluster 
level for multiple comparisons using False Discovery Rate (FDR).
For PIB analyses, mean SUVR was computed using the Clark method(Clark, Schneider, 
2011). SUVR’s were compared in all regions between the one subject with SP (subject AJ) 
and 4 without by Mann-Whitney U tests.
3 Results
3.1 Subjects
Ten subjects affected by pathogenic PSEN1 mutations were studied, including 3 with SP and 
7 without (see Table 1 for demographics and clinical information). All 3 subjects with SP 
were unable to walk independently whereas none of the 7 non-SP subjects had any 
difficulties with ambulation. All ten had cognitive symptoms with 5 having CDR scores of 
0.5 (2 with SP, 3 without), 2 w/CDR scores of 1 (both without SP, 1 w/CDR score of 2 (no 
SP), and 2 w/CDR scores of 3 (one with and one without SP). All three subjects with SP 
were males with the A431E PSEN1(Murrell et al, 2006; Yescas et al, 2006) mutation while 
the 7 without SP were more diverse with regards to gender (5 were female) and mutation (1 
with the A431E, 2 with the G206A(Athan et al, 2001), and one each with the 
R269H(Gomez-Isla et al, 1997), S212Y(Ringman, Gylys, 2011), I238M(Ting et al, 2014), 
and M146L(Morelli et al, 1998) PSEN1 mutations). Subjects with and without SP were 
comparable with regards to mean age (48.7 vs. 54.7), disease duration (5.3 years), MMSE 
(15.3 vs. 18.0), and CDR sum of boxes score (6.7 vs. 6.9). Notably, 2 of the 3 subjects with 
SP were of the APOE ε3/4 genotypes and the remaining subject with SP had the APOE ε2/3 
genotype. Six of the seven subjects without SP had the APOE ε3/3 genotype with the 
remaining subject having the APOE ε4/4 genotype.
3.2 DTI Results
Relative to those without SP, decreased FA was seen in subjects with SP in widespread areas 
of white matter including in the corpus callosum, occipital, parietal, and frontal lobes. It 
extended into the corona radiata and centrum semiovale and also into the precentral gyri 
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among other gyri bilaterally (Figure 1A). Increased MD was also seen in comparable areas 
except with extension into the right temporal lobe (Figure 1B). Comparison of axial (L1) 
diffusivity did not demonstrate any differences between persons with and without SP while 
radial diffusivity (L2 & L3) was increased in persons with SP in areas overlapping those of 
FA decrease (Figure 1C).
3.3 White Matter Hyperintensities
The volume of WMH and Fazekas score did not differ between those with and without SP 
(Table 2). However, it is noteworthy that all the SP participants presented a Fazekas’ score 
above 0 and a volume of WMH >10,000mm3, thus abnormal white matter readily visible on 
MRI. Interestingly, the variability in the extended volume of WMH in the SP group (n=3) 
was low, while the non SP group (n=5) displayed more variability. The non SP group 
presented only one subject with a volume of WMH > 10,000mm3 and 2 subjects with 
normal WM assessed by Fazekas’ score.
3.4 Volumetric analyses
There were no statistically significant differences in the volumes of any cerebral structures 
(cerebellum, caudate, putamen, pallidum, amygdala, hippocampi) or cortical thickness in 
any region (temporal, frontal, parietal, or occipital) between persons with and without SP 
though the means of all such measures were numerically lower in persons with SP (Table 2).
3.5 Microhemorrhage count
MCH count was available for all 3 subjects with SP and on 6/7 of those without SP. Number 
of MCHs was not statistically different between groups. Notably, however, 2 of the 3 
persons with SP had MCH counts of greater than 100 (see Figure 2) while only one of the 6 
subjects without SP had MCHs (n = 73) (Table 2).
3.6 PiB PET
PiB PET was available and analyzed for 4 persons without SP and one subject with SP (AJ). 
There were no areas of significantly different SUVR between AJ and the 4 without SP 
including in the sensorimotor cortices and basal ganglia (see table 3 for representative areas, 
Figure 3) though AJ had the numerically lowest mean cortical binding potential (0.21 
relative to a mean of 0.84, range from 0.24 – 1.18, threshold for positivity = 0.18, Figure 3). 
SUVR for the left and right sensorimotor cortices were 1.15 and 1.06 in AJ (means SUVRs 
in these areas for the 4 subjects without SP, 1.97 and 1.99, respectively). AJ had relatively 
selective increased amyloid signal in the thalami but this was not significantly different from 
those without SP.
3.7 Electrophysiological Studies
In AJ, CMCT of the right lower extremity was markedly slow with a latency of 34.8 ms, 
(normal < 16.5 ms) while that of the right upper extremity was normal at 8.2 ms (normal < 
9.7 ms). SSEPs were mildly slowed in the lower (N8 - P37 latency 39.1 ms, normal < 36.0 
ms) but not upper extremities N9 - N20 = 9.7 ms, normal < 10.6 ms).
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4 Discussion
In this study, we performed comprehensive characterization of PSEN1 mutation carriers 
with and without SP in an attempt to elucidate the underlying pathophysiology. We found 
robust and widespread decreases in white matter integrity as indexed by decreased FA, 
increased MD, and apparent length-dependent slowed central conduction times including 
SSEPs. FA decreases and MD increases were seen in white matter underlying motor cortex 
consistent with the conduction abnormalities observed. These findings in the context of 
relatively preserved gray matter volumes and lack of amyloid deposition in sensorimotor 
cortex in one subject are supportive of an effect of the A431E PSEN1 mutation on white 
matter in part independent of APP mismetabolism.
Previous studies regarding the pathology associated with PSEN1-related SP are limited. 
There is a frequent, though not invariable(Kwok et al, 1997; Shrimpton et al, 2007), 
association between SP and atypical “cotton-wool” amyloid plaques (“CWP”) demonstrated 
on neuropathologic examination(Houlden et al, 2000) and CWPs are present in persons 
dying with the A431E PSEN1 mutation(Roher et al, 2013). CWPs are large amyloid plaques 
lacking neuritic cores that consist largely of Aβ42 species truncated near the amino 
terminal(Miravalle et al, 2005). Though occasionally reported in LOAD(Le et al, 2001) they 
are most frequently associated with PSEN1 mutations that cause extremely high levels of 
Aβ42 to be produced(Houlden, Baker, 2000; Karlstrom, Brooks, 2008), suggesting the 
possibility of qualitative or quantitative differences in APP processing in their genesis. In 
light of the variable co-occurrence of SP and CWPs(Yokota, Terada, 2003) however, the 
mechanism through which they are linked is unclear. Verkkoniemi et al(Verkkoniemi et al, 
2001) found abundant CWPs in medial primary motor cortex associated with degeneration 
of the lateral corticospinal tract, suggesting a cause-and-effect relationship. Rudzinski et al 
similarly observed degeneration of the corticospinal tracts with sparing of the medial 
lemniscus in a patient with SP and a PSEN1 mutation but did not find disproportionate 
involvement of the motor cortex with AD pathology(Rudzinski, Fletcher, 2008). The lack of 
significant PiB signal in the sensorimotor cortex in the one patient in our study with SP 
assessed using this modality argues against fibrillar amyloid plaques playing a direct role in 
the development of this corticospinal sign. A previous PiB study in “variant” PSEN1-related 
AD with SP similarly failed to find excessive amyloid deposition in sensorimotor cortex but 
did find disproportionate deposition in the striatum(Koivunen et al, 2008) as did a recent 
study of a single subject with SP(Lyoo et al, 2016). Importantly, tau PET imaging using 18F-
AV-1451 was performed in this latter study which revealed increased signal in sensorimotor 
cortex, particularly contralateral to the hemibody which was most affected by spasticity. Tau 
deposition was higher in widespread areas of cortex relative to controls with LOAD 
including in medial and lateral parietal lobes, inferior temporal lobes, and occipital lobes. 
This is consistent with cortical neurofibrillary pathology being a correlate, and potentially 
causative, of the white matter pathology we identified with DTI. It should be noted however, 
that PiB does not bind equally to all forms of amyloid plaques(Ringman et al, 2012), and the 
nature of its binding to the CWPs frequently present in PSEN1-related SP has not to our 
knowledge been well characterized.
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O’Riordan et al described SP in PSEN1-related AD associated with extensive cerebral 
amyloid angiopathy (CAA) and white matter changes presumably of ischemic origin and 
suggested a causal relationship(O'Riordan et al, 2002). MCHs were extensive in two of the 
three subjects with SP in our study and interestingly, these two had the APOE ε2/3 and 3/4 
genotypes with the remaining subject with SP having the 3/4 genotype as well. An 
association of diffusely diminished FA with lobar MCHs in APOE ε4 carriers has been 
reported and was interpreted as the MCHs representing the “tip of the iceberg” with regards 
to more subtle and diffuse affectation of white matter(Akoudad et al, 2013). The relationship 
of MCHs with SP is not clear however, as not all subjects with SP have MCHs and clearly 
non-ADAD patients with CAA and MCHs do not typically develop SP. MCHs do not appear 
to explain our DTI findings in that two of the subjects in the current study were siblings of 
whom one had SP and no MCHs (APOE ε3/4) while the other (APOE ε3/3) had 73 MCHs 
but no SP. The subject with MCHs but without SP had numerically “more normal” DTI 
indices. In addition, how MCHs would give rise to the SSEPs abnormalities (see below) is 
unclear. We hypothesize that any relationship of MCHs and APOE genotype with SP is an 
indirect one though further studies are required to better define this.
We found increased MD in persons with SP in a pattern similar to, but to a greater extent 
than that of decreased FA. In a prior study of seven presymptomatic ADAD mutation 
carriers investigators found increases in MD but not FA, suggesting changes in mean 
diffusivity may be a more sensitive measure of white matter changes in this population(Li et 
al, 2015). When axial and radial diffusivity were separately compared between persons with 
and without SP, we found increased radial diffusivity in persons with SP in a pattern similar 
to the FA differences but no differences in axial diffusivity. Increased radial diffusivity has 
been interpreted to represent pathology of myelin rather than axons(Song, Sun, 2003; Song 
et al, 2002). The pathology underying DTI changes in AD is unclear, with reports of both 
increased radial and axial diffusivity(Back et al, 2011; Sun et al, 2014). Though loss of 
corticospinal projection neurons (Betz cells) as reflected in the neurofibrillary pathology in 
motor cotex seen in the study by Lyoo et al(Lyoo, Cho, 2016) might account for the spastic 
paraparesis, a direct effect of the A431E mutation on myelin cannot be ruled out. Such a 
direct effect in carriers of PSEN1 mutations is suggested by a gene expression study in 
which mRNA for Presenilin-1 was highly co-expressed with myelin proteins(Miller et al, 
2008). However, PSEN1 mutations might also lead to white matter abnormalities and SP 
through other effects on axons and axonal transport as evidenced in studies of transgenic 
animals(Pigino et al, 2003; Wirths et al, 2006). Persons with PSEN1 mutations, including 
the A431E mutation and others giving rise to spastic paraparesis, have been shown to have 
biochemical abnormalities in white matter distinct from that of late-onset AD(Roher, 
Maarouf, 2013).
We previously reported substantially diminished FA in a cohort of presymptomatic persons 
with ADAD mutations (Ringman, O'Neill, 2007). Though those findings appeared robust, 
such differences are not always found during the presymptomatic phase of the autosomal 
dominant AD (Sanchez-Valle et al, 2016). Notably, only one of the nine mutations studied in 
that report has been described as being associated with SP(Karlstrom, Brooks, 2008; Llado 
et al, 2010)(http://www.molgen.ua.ac.be/admutations) and 11 of the 23 subjects in our initial 
paper were from families with the A431E PSEN1 mutation. Though none had SP at the time 
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of their participation in that study, our results are consistent with the A431E PSEN1 
mutation having a particular effect on white matter integrity which is greatest in association 
with SP.
Supportive of a direct effect of the A431E PSEN1 mutations on neuronal projections in the 
etiology of SP is the finding of delayed SSEPs from the lower extremities in our subject. 
SSEPs are thought to reflect conduction through the medial lemniscus and therefore our 
findings are consistent with abnormalities in the projections arising from the dorsal root 
ganglion or their rostral extension from the nuclei cuneatus and gracilis in the medulla. 
Though upregulation of APP has been described in the dorsal root ganglion(Nishimura et al, 
2003) such conduction abnormalities have not, to our knowledge, been described in LOAD 
and therefore may represent an effect of the A431E PSEN1 mutation independent of APP 
processing. Note that in the one neuropathological report in which the lemniscal pathways 
were described in a patient with PSEN1-related SP, no gross abnormalities were 
seen(Rudzinski, Fletcher, 2008) and SSEPs were described as being normal in the subject 
with spastic paraparesis imaged with tau PET in the study of Lyoo et al(Lyoo, Cho, 2016).
Though we found imaging and electrophysiological evidence of widespread white matter 
abnormalities in PSEN1 mutation-related SP, there are limitations in our ability to determine 
the underlying mechanism. Our groups were not as comparable with regards to gender and 
distribution of APOE genotype as would have been ideal. Though all persons with SP were 
males in this study, we have seen females with the SP associated with the A431E PSEN1 
mutation. In post-hoc analyses we performed comparisons of DTI measures between the 3 
males with SP and the two males without. No statistically significant differences were seen 
in specific anatomical areas. However, mean white matter FA was higher (0.43 vs. 0.38) and 
MD lower (0.00077 vs. 0.00083) in males without SP than in those with, suggesting the 
effects seen were more likely to be related to the presence of SP than to gender.
Though all 3 SP subjects in our study had non-ε3/3 APOE genotypes, one non-SP subject 
was of the APOE ε4/4 genotype. SP is characteristic of specific PSEN1 mutations rather 
than of PSEN1 mutations in general in the context of a non-APOE ε3 allele. Similarly, the 
overabundance of MCH’s (and presumably, CAA) in persons with SP does not easily 
explain this clinical feature. However, a limitation of our study is that MCH’s were 
quantified from either GRE or SWI images in different subjects, limiting our ability to 
compare them. Importantly, with the exception of the one sibling with the A431E PSEN1 
mutation without SP, the remaining 6 subjects without SP all had mutations that have not 
been reported as being associated with SP, enhancing our ability to isolate the effects of a 
PSEN1 mutation consistently associated with this atypical feature. In additional post-hoc 
analyses we compared diffusion measures between the 3 subjects with SP to the one subject 
with the A431E PSEN1 mutation but without SP using the approach described above. 
Though no significant differences were found in specific tracts, average white matter FA was 
numerically higher (0.42 vs. 0.39) and MD lower (0.00079 vs. 0.00083) in the subject 
without SP compared to those with SP. This is consistent with the differences seen being 
more closely related to SP than to the A431E PSEN1 mutation per se. Similar 
comprehensive evaluations, including identical imaging, electrophysiological and 
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biochemical assessments, of a larger number of subjects with and without SP and the A431E 
and other PSEN1 mutations should help clarify the etiology of SP in this context.
In this study we have documented widespread DTI abnormalities despite relatively 
preserved gray matter volumes in persons with SP associated with the A431E PSEN1 
mutation. With the single subject with SP that underwent electrophysiological studies and 
amyloid imaging showing conduction abnormalities in the corticospinal, transcallosal, and 
lemniscal tracts in the context of insignificant PiB signal in relevant cortical regions, our 
data support the presence of diffuse white matter abnormalities that may be independent of 
fibrillar amyloid deposition in the etiology of this unusual clinical feature in persons with the 
A431E PSEN1 mutation.
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Highlights
Highlights of the current paper are:
1. We found widespread abnormalities of white matter using DTI in 
persons with PSEN1-spastic paraparesis that were not confined to the 
corticospinal tract, relative to persons with PSEN1 mutations without 
spastic paraparesis.
2. There was a relative paucity of amyloid signal in the cortex of a subject 
with spastic paraparesis and clearly not increased signal in the 
sensorimotor cortex.
3. Electrophysiological studies confirmed slowed motor evoked potentials 
to the legs and suggested slowed somatosensory conduction from the 
legs as well, suggesting widespread white matter abnormalities.
In aggregate these data suggest that spastic paraparesis in PSEN1-related AD is but one 
sign of widespread abnormalities of white matter that may arise independently of 
aberrant Abeta metabolism.
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Figure 1. 
A) Voxels in which fractional anisotropy was significantly lower (p < 0.05, FDR corrected) 
in 3 subjects with PSEN1-related SP relative to 7 without. B) Voxels in which MD was 
higher and C) radial diffusivity higher in subjects with SP. There were no areas were axial 
diffusivity differed between groups.
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Figure 2. 
Extensive lobar microhemorrhages seen on susceptibility-weighted MRI in “AJ” a 49 year-
old man carrying the A431E PSEN1 mutation with spastic paraparesis. Note the predilection 
for the parietal and occipital lobes.
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Figure 3. 
PiB images in a subject with SP due to the A431E PSEN1 mutation (“AJ”) and four without 
SP. Note the overall reduced PiB signal in AJ except for relatively selective deposition in the 
thalamus.
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Table 1
Demographic, clinical, and genetic characteristics of the study population. P-values denote significance for 
Mann-Whitney U tests, Chi-Square tests, and Fisher’s exact tests as appropriate.
PSEN1 mutation carriers 
with SP (n = 3)
PSEN1 mutation carriers without SP 
(n = 7)
Mean age in years (s.d.) 48.7 (1.5) 54.7 (8.6) p = 0.38
Mean duration of cognitive and/or motor symptoms 
in years (s.d.)
5.3 (2.5) 5.3 (6.0) p = 0.52
Mean years after age of median family-specific age 
of dementia diagnosis (s.d.)
0.0 (5.7) 2.7 (6.4) p = 0.53
Gender, # female (%female) 0 (0%) 5 (71%) p = 0.17
APOE genotype distribution 3/4 (n = 2), 2/3 (n = 1) 3/3 (n = 6), 4/4 (n = 1) p = 0.02
Specific mutations A431E (all 3) A431E (n =1), G206A (n = 2), I238M, 
M146L, R269H, S212Y (each = 1)
p = 0.27
Mean MMSE (s.d.) 15.3 (10.4) 18.0 (10.7) p = 0.67
Mean CDR total scores 0.5 (n= 2), 3 (n = 1) 0.5 (n = 3), 1 (n = 2), 2 (n = 1), 3 (n = 
1)
p = 0.83
Mean CDR sum of boxes (s.d.) 6.7 (7.2) 6.9 (6.5) p = 0.83
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Table 2
Quantitative imaging variables compared between symptomatic PSEN1 mutation carriers with and without SP 
by two-sided t-tests. *Microhemorrhage counts greater than 100 were quantified as 100. Comparisons were 
made using Mann-Whitney U tests.
PSEN1 mutation carriers with 
SP (n = 3)
PSEN1 mutation carriers without SP (n = 
7)
Mean cerebellar volume mm3 (s.d.) 122,053 (4,708) 128,625 (17,892) p = 1.00
Mean caudate volume mm3 (s.d.) 6,389 (784) 6,854 (620) p = 0.38
Mean putamen volume mm3 (s.d.) 8,617 (1,534) 9,248 (1128) p = 0.67
Mean pallidum volume mm3 (s.d.) 2,908 (124) 3,116 (218) p = 0.27
Mean amygdala volume mm3 (s.d.) 2,787 (672) 2,598 (652) p = 0.83
Mean right hippocampal volume mm3 (s.d.) 2,982 (331) 3,146 (720) p = 0.67
Mean left hippocampal volume mm3 (s.d.) 3,000 (215) 3,112 (639) p = 0.83
Mean occipital cortex thickness mm (s.d.) 1.72 (0.05) 1.90 (0.15) p = 0.12
Mean temporal cortex thickness mm (s.d.) 2.66 (0.33) 2.83 (0.16) p = 0.38
Mean parietal cortex thickness mm (s.d.) 2.05 (0.06) 2.18 (0.22) p = 0.67
Mean frontal cortex thickness mm (s.d.) 2.39 (0.11) 2.44 (0.09) p = 0.67
Mean WMH volume – mm3 (s.d.) 17,978 (3,651) 9,491 (15,954) (n = 5) p = 0.25
Mean Fazekas score (s.d.) 2.0 (1.0) 1.2 (1.3) (n = 5) p = 0.39
# microhemorrhages* 66.7 (57.7) 12.2 (29.8) (n = 6) p = 0.17
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Table 3
SUVRs for various cerebral regions in one carrier of the A431E PSEN1 mutation with SP relative to 4 PSEN1 
mutation carriers without SP.
Subject with spastic paraparesis (AJ) 4 subjects without spastic paraparesis
Mean cortical binding potential 0.21 0.84 (0.42)
Mean left posterior cingulate cortex (s.d.) 1.46 2.57 (0.72)
Mean right posterior cingulate cortex (s.d.) 1.58 2.36 (0.76)
Mean left primary visual cortex (s.d.) 1.52 2.20 (0.73)
Mean right primary visual cortex (s.d.) 1.50 2.06 (0.59)
Mean left sensorimotor cortex (s.d.) 1.06 1.97 (0.30)
Mean right sensorimotor cortex (s.d.) 1.15 1.99 (0.34)
Mean left thalamus (s.d.) 1.72 1.93 (0.65)
Mean right thalamus (s.d.) 1.86 2.00 (0.49)
Mean left caudate nucleus (s.d.) 1.21 2.02 (0.65)
Mean right caudate nucleus (s.d.) 1.08 2.07 (0.52)
Mean reft cerebellum (s.d.) 1.00 1.02 (0.00)
Mean right cerebellum (s.d.) 0.99 0.98 (0.00)
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